RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • April 24th, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 24th, 2018 Company Industry JurisdictionThis Research Collaboration and License Agreement (the “Agreement”) is entered into as of December 28, 2017 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and Sangamo Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 (“Sangamo”). Pfizer and Sangamo may each be referred to herein individually as a “Party” and collectively as the “Parties.”
research collaboration and license AGREEMENTResearch Collaboration and License Agreement • March 1st, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 1st, 2018 Company Industry JurisdictionThis Research Collaboration and License Agreement (the “Agreement”) is entered into as of December 28, 2017 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and Sangamo Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 (“Sangamo”). Pfizer and Sangamo may each be referred to herein individually as a “Party” and collectively as the “Parties.”